# Razelle Kurzrock

Source: https://onco.cc/people/razelle-kurzrock/  
OnCo record `razelle-kurzrock` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Precision oncology pioneer who showed that matching drugs to each patient's mutations, in combination, improves outcomes.

## Summary

Razelle Kurzrock (Medical College of Wisconsin; formerly MD Anderson and UC San Diego) built one of the first large precision oncology programmes and led the I-PREDICT trial, which showed that individualised combination therapy matched to a higher fraction of a tumour's alterations improves progression-free survival. She founded the WIN Consortium and the field's methodology for N-of-1 matching, and has led early-phase trials in rare and refractory cancers.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: precision-oncology; early-phase; n-of-1
- Role: Professor of Medicine, Medical College of Wisconsin; Linda T. and John A. Mellowes Endowed Chair in Precision Oncology
- Specialisms: Precision oncology; Early-phase trials; N-of-1 combination therapy; Rare cancers

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Kurzrock%20R%5BAuthor%5D%20precision%20oncology%20matched

## Connected records

- technologies: [AI trial matching & clinical decision support](https://onco.cc/technologies/ai-trial-matching/), [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/)
- institutions: [Medical College of Wisconsin Cancer Center](https://onco.cc/institutions/mcw-cancer-center/)
- terms: [Master protocol (platform, basket and umbrella trials)](https://onco.cc/terms/master-protocol/)
- trials: [DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours](https://onco.cc/trials/dart-s1609/), [I-PREDICT](https://onco.cc/trials/i-predict/), [WINTHER](https://onco.cc/trials/winther/)

---
JSON: https://onco.cc/api/v1/entities/razelle-kurzrock.json